Abstract
Crizotinib has a well-established role in ROS1+ non-small cell lung cancer (NSCLC). Few data exist on the activity of the drug in controlling brain disease in ROS1+ patients. The METROS trial was a multicentric phase II trial aiming at investigating the efficacy of crizotinib in pretreated patients with NSCLC and MET deregulation (amplification or exon 14 mutations) or ROS1 rearrangements. The study confirmed the efficacy of the drug in ROS1+, with modest activity in the MET-deregulated cohort (Landi L et al., Clin Cancer Res 2019).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
